[Frontiers in Bioscience 8, e157-171, January 1, 2003]


Gabriele Grunig and Viswanath P. Kurup

St. Luke's Roosevelt Hospital, Columbia University, 432 W 58th Street, Laboratory 504, New York, NY 10019, USA and Allergy-Immunology Division, Medical College of Wisconsin, Research Service 151, V A Medical Center, 5000 W National Avenue, Milwaukee, WI 53295, USA


1. Abstract
2. Introduction
3.Models using Antigen Extract & Conidia
3.1. Immune and inflammatory Response in A. fumigatus antigen sensitized animals
3.1.1. Lung Inflammation
3.1.2. Airway Hyperreactivity
3.1.3. Airway Remodeling
3.2. T cell Response
3.3. Cytokine Response
3.3.1. IL-13
3.3.2. IL-4
3.3.3. IL-5
3.3.4. IL-10
3.4. Antibody Response
3.5. Eosinophil Response
3.6. Chemokine Response
3.6.1. C10 / CCL6
3.6.2. CCR1
3.6.3. CCR2 and MCP1 / CCL2
3.6.4. CXCR2
3.6.5. CCR5 and RANTES/ CCL5
4. Models using Recombinant Antigens
5. Immunotherapy
5.1. Recombinant Allergens & Peptides
5.2. Immunostimulatory Oligonucleotides
6. Future Perspectives
7. Acknowledgements
8. References


Experimental animal models of Allergic Bronchopulmonary Aspergillosis (ABPA) serve several purposes. Both common and distinct pathological features occurring in natural and experimental diseases are of great interest as they serve to identify the key elements in the pathogenesis. Experimentally induced diseases can be modeled to understand the various parameters such as antigen and route of exposure, genetic background and the role of response modifiers in the disease process. Furthermore, animals with targeted gene-deletion or with insertion of transgenes have been studied to define the roles of specific cells, receptors and mediators in the pathogenesis. The resulting conclusions have been used to formulate hypothesis, which have to be tested for their application to human disease.